Trovagene holds a license to US patent 8,222,370 and the corresponding group of US and foreign patent applications around NPM.

Trovagene chief technology officer Charlie Rodi said the company continues to expand patient access to the NPM1 marker.

"Physicians need accurate tools to assess prognosis, select therapies and evaluate for bone marrow transplant," Rodi added.

"Use of this marker can help physicians more effectively treat patients with AML."